A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 4, 1999, Pages 316-322

  Tranchand, Brigitte ^a   Amsellem, Carole ^a   Chatelut, Etienne ^b   Freyer, Gilles ^c   Iliadis, Athanassios ^d   Ligneau, Blandine ^c   Trillet Lenoir, Véronique ^c   Canal, Pierre ^b   Lochon, Isabelle ^b   Ardiet, Claude Joseph ^a  

^a CENTRE LÉON BÉRARD   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Bayesian estimation; Etoposide; Pharmacokinetics

Indexed keywords

DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAYES THEOREM; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARCINOMA; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; REPRODUCIBILITY OF RESULTS; SELECTION BIAS;

EID: 0032982127     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050901     Document Type: Article

References (38)

1. 1. Aisner J, Lee EJ (1991) Etoposide: current and future status. Cancer 67: 215-219
2. 2. Atkinson AC, Donev AN (1992) Optimum experimental designs. Oxford Science Publications, Oxford
3. 3. Bennett CL, Sinkule JA, Schilsky RL, Conley BA, Senekjian E, Choi KE (1987) Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Res 47: 1952-1956
4. 4. Berry BW, Erlichman C (1996) Clinical pharmacology of anticancer drugs. In: Schilsky RL, Milano GA, Ratain MJ (eds) Principles of antineoplastic drug development and pharmacology. Marcel Dekker, New York, pp 88-92
5. 5. Bressolle F, Bologna C, Edno L, Bernard JC, Gomeni R, Sany J, Combe B (1996) A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. Eur J Clin Pharmacol 49: 285-292
6. 6. Bressolle F, Gouby A, Martinez JM, Joubert P, Saissi G, Guillaud R, Gomeni R (1996) Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Chemother 40: 1682-1689
7. 7. Burton ME, Brater DC, Chen PS, Day RB, Huber PJ, Vasko MR (1985) A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther 37: 349-357
8. 8. Chao NJ, Stein AS, Long D, Negrin R, Amylon M, Wong R, Forman S, Blume K (1993) Busulfan/etoposide - initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood 81: 319-323
9. 9. Cunningham D, McTaggart L, Soukop M, Cummings J, Forrest GJ, Stuart JFB (1986) Etoposide: a pharmacokinetic profile including an assessment of bioavailability. Med Oncol Tumor Pharmacother 3: 95-99
10. 10. D'Argenio DZ (1981) Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 9: 739-756
11. 11. Desoize B, Marechal F, Cattan A (1993) Corrélations entre la pharmacodynamie clinique et la pharmacocinétique clinique du cisplatine et de l' étoposide. Ann Biol Clin 51: 125-128
12. 12. D'Incalci M, Farina P, Sessa C (1982) Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol 7: 141-145
13. 13. Hill M (1986) BMDPC: BMDP statistical software for micro-computers. Psychopharmacol Bull 22: 301-306
14. 14. Holz JB, Köppler H, Schmidt L, Fritsch HW, Pflüger KH, Jungclas H (1995) Limited sampling models for reliable estimation of etoposide area under the curve. Eur J Cancer 31A: 1794-1798
15. 15. Hurley SF, Neil JJ (1988) A comparison of the accuracy of a least squares regression, a Bayesian, Chiou's and the steady state clearance method of individualizing theophylline dosage. Clin Pharmacokinet 14: 311-320
16. 16. Iliadis A, Bachir-Rabo M, Bruno R, Favre R (1985) Bayesian estimation and prediction of clearance in high-dose methotrexate infusion. J Pharmacokinet Biopharm 13: 101-115
17. 17. Iliadis A, Brown AC, Huggins ML (1992) APIS: a software for identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Comput Methods Programs Biomed 38: 227-239
18. 18. Joel S (1996) The clinical pharmacology of etoposide: an update. Cancer Treat Rev 22: 179-221
19. 19. Joel SP, Heap L, Robbins S, Clarke PI, Slevin ML (1990) A limited sampling strategy for the calculation of etoposide pharmacokinetics (abstract). Proc Am Soc Clin Oncol 9: 260
20. 20. Joel SP, Shah R, Slevin ML (1994) Etoposide dosage and pharmacodynamics. Cancer Chemother Pharmacol 34: S69-S75
21. 21. Karlsson MO, Port RE, Ratain MJ, Sheiner LB (1995) A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther 57: 325-334
22. 22. Mick R, Ratain MJ (1991) Modeling interpatient pharmacodynamic variability of etoposide. J Natl Cancer Inst 83: 1560-1564
23. 23. Miller AA, Stewart CF, Tolley EA (1990) Clinical pharmacodynamics of continuous-infusion etoposide. Cancer Chemother Pharmacol 25: 361-366
24. 24. Miller A, Tolley E, Niel H, Griffin J, Mauer A (1993) Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 11: 1179-1188
25. 25. Minami H, Horio Y, Sakai S, Saka H, Shimokata K (1991) Pharmacokinetics of etoposide infused over three days: concomitant infusion with cisplatin. Jpn J Clin Oncol 21: 400-405
26. 26. Pfluger KH, Hahn M, Holz JB, Schmidt L, Köhl P, Fritsch HW, Jungclas H, Havemann K (1993) Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters and clinical conditions. Cancer Chemother Pharmacol 31: 350-356
27. 27. Ratain MJ, Mick R, Schilsky RL, Vozelzang NJ, Berezin F (1991) Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 9: 1480-1486
28. 28. Sheiner LB, Beal SL (1981) Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data. J Pharmacokinet Biopharm 9: 635-651
29. 29. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9: 503-512
30. 30. Sheiner LB, Rosenberg B, Melmon KL (1972) Modeling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 5: 441-459
31. 31. Sheiner LB, Halkin H, Peck C, Rosenberg B, Melmon KL (1975) Improved computer-assisted digoxin therapy. A method using a feedback of measured serum digoxin concentration. Ann Intern Med 82: 619-627
32. 32. Sinkule JA, Hutson P, Hayes FA, Etcubanas E, Evans WE (1984) Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. Cancer Res 44: 3109-3113
33. 33. Slevin ML, Clark PI, Joel SP, Malik S, Osborne RJ, Gregory WM, Lowe DG, Reznek RH, Wrigley PFM (1989) A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7: 1333-1340
34. 34. Spitzer TR, Cottler-Fox M, Torrisi J, Cahill R, Greenspan A, Lynch M, Deeg HJ (1989) Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant 4: 559-565
35. 35. Stahelin H, Wartburg A von (1989) From podophyllotoxin glucoside to etoposide. Prog Drug Res 33: 169-266
36. 36. Stewart CF (1994) Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol 34: S76-S83
37. 37. Strömgren AS, Sorensen BT, Jakobsen P, Jakobsen A (1993) A limited-sampling method for estimation of the etoposide area under the curve. Cancer Chemother Pharmacol 32: 226-230
38. 38. rVinks AA, Mouton JW, Touw DJ, Heijerman HGM, Danhof M, Bakker W (1996) Population pharmacokinetices of ceftazidime in cystic patients analyzed by using a nonparametric algorithm and optimal sampling strategy. Antimicrob Agents Chemother 40: 1091-1097